Hydroxicitrate (HCA) Presentation at American College of Nutrition Meeting Confirms Glykon Patents

Georgetown University HCA study presented at 46th Annual Meeting of the American College of Nutrition confirms Glykon patents covering insulin metabolism, blood pressure and inflammation.

For Immediate Release:

Las Vegas, NV, (PRWEB) November 5, 2005 -- A presentation at the 46th American College of Nutrition Annual Meeting examined blood pressure, insulin levels and inflammation with the oral intake of three forms of hydroxycitrate (HCA) at doses resembling those used by humans. (1) All HCA forms significantly lowered blood pressure and trended towards reduced CRP and TNF-alpha, potassium-magnesium HCA significantly. Potassium and potassium-magnesium HCA dramatically improved insulin sensitivity, but the potassium-calcium HCA showed no benefit. The weaker showing of potassium-calcium HCA in most areas may be the result of limited assimilation due to the presence of calcium and also the presence of the undesirable HCA lactone. Dutch scientists have published similar results regarding potassium-calcium HCA. (2) Differences in the quality of HCA salts on the market may be responsible for the inconsistent findings of researchers. (3) Liquid HCA and HCA salts delivered in acidic beverages are characterized by elevated lactone levels.

Glykon Technologies Group, LLC has published similar findings. In United States Patent 6,476,071, the company reported that rats on a high fat diet received no weight control benefits from potassium-calcium HCA, whereas potassium hydroxycitrate strongly reduced weight gain. It was found that more fully and properly reacted potassium salts delivered greater benefits. William Matheny, a partner at Glykon, affirms that the company produces only fully reacted HCA salts. “We are committed to efficacy. Our HCA products not only are fully reacted, but also make use of special patented delivery systems to avoid interaction with food and other ingredients.”

Glykon Technologies Group discovered and holds the rights to make claims regarding the impact of HCA on the regulation of insulin and blood sugar (Syndrome X), modulation of leptin and glucocorticoids, improvements in bone mineralization, the regulation of immune function, normalization of blood pressure and control of inflammation. The company also has patented multiple technologies greatly expanding the range of available delivery forms for HCA as well as improving its assimilation and activity. Based in Las Vegas, Nevada, Glykon specializes in research, intellectual property development and licensing. On February 4, 2005, Glykon terminated its licensing agreement with Renaissance Herbs, Inc. covering uses and delivery systems for (–)-hydroxycitric acid and related products.

(1) Clouatre D, Preuss H, et al. Hydroxycitrate at Physiologic Levels Influences Insulin Sensitivity, Blood Pressure and Inflammation in an Animal Model.
(2) Louter-van de Haar J, et al. Comparison of the effects of three different (–)-hydroxycitric acid preparations on food intake in rats. Nutr Metab (Lond). 2005 Sep 13;2(1):23.
(3) Wielinga PY, et al. Hydroxycitric acid delays intestinal glucose absorption in rats. Am J Physiol Gastrointest Liver Physiol. 2005 Jun;288(6):G1144-9.

For more details contact:

Glykon Technologies Group, LLC
20885 Redwood Road #325
Castro Valley CA. 94546

Visit Glykon Technologies Group, LLC on the web at http://www.glykon.com.

###